Skip to main content
. 2018 Jan 14;24(2):226–236. doi: 10.3748/wjg.v24.i2.226

Figure 1.

Figure 1

Serum miR-93-5p expression is increased in hepatitis C virus-1b-infected patients. A: The linearity of miR-93-5p quantification; B: Box shows serum miR-93-5p concentrations in 84 patients with HCV-1b infection, compared with 84 healthy subjects; C: Box shows serum miR-93-5p concentrations in 50 HCV-1b-infected patients with pegylated IFNα sensitivity and 34 HCV-1b-infected patients with pegylated IFNα resistance, compared with 84 healthy subjects; D: Scatter shows serum miR-93-5p concentrations in 84 healthy subjects and 50 HCV 1b-infected patients with pegylated IFNα sensitivity before or after treatment; E: Scatter shows serum miR-93-5p concentrations in 84 healthy subjects and 34 HCV 1b-infected patients with pegylated IFNα resistance before or after treatment. HCV: Hepatitis C virus; IFNα: Interferon-α.